About Biofluidica
Biofluidica is a Healthcare company based in Chapel Hill (United States) founded in 2007 by Steven A Soper. Liquid biopsy tests utilizing CTCs are provided for cancer detection. Biofluidica has raised $18.12 million across 11 funding rounds from investors including NIH, HHS and Mizzou. Its chief executive, as recorded, is Greg Studdard. Biofluidica offers products and services including LiquidScan, Exosome Isolation, Fetal Cell Isolation, and CTC Isolation. Its focus areas include Life Sciences, Genomics, Applied Genomics and Clinical Genomics. Its legal entity is BIOFLUIDICA, INC. Its competitors include Guardant Health, GRAIL and Thrive Earlier Detection; 3 of its 3 listed competitors have raised funding.
Company details
Biofluidica was founded in 2007 and is based in Chapel Hill, United States, within the biotechnology sector. Operations focus on liquid biopsy systems that employ antibody-coated capture beds to isolate circulating tumor cells from blood samples. Clinical validation has been achieved for pancreatic, colorectal, ovarian, and breast cancers, enabling analysis for diagnostic purposes.
- Total Equity Funding$18.12M (USD)
in 11 rounds
- InvestorsNIH
& 2 more
Products & Services of Biofluidica
Biofluidica offers a comprehensive portfolio of products and services, including LiquidScan, Exosome Isolation, Fetal Cell Isolation, and CTC Isolation.
Automates isolation of rare cells and exosomes for diagnostics
Enables exosome extraction from samples for research analysis
Facilitates isolation of trophoblasts for prenatal testing
Supports isolation of circulating tumor cells from blood
Apps and channels of Biofluidica
its YouTube channel BioFluidica has 4 subscribers and 6 videos.
Videos from Biofluidica
The most watched videos on Biofluidica's YouTube channel, BioFluidica (4 subscribers). Click a video to play it here.
More on BioFluidica.
Funding Insights of Biofluidica
Biofluidica has successfully raised a total of $18.12M across 11 strategic funding rounds. This substantial capital infusion reflects strong investor confidence in the company's business model, growth potential, and market opportunities. The funding enables strategic expansion, product development, market penetration, and operational scaling to drive long-term value creation and competitive advantage.
- Total Funding $18.12M
- Total Rounds 11
- First Round $399,673
(Sep 2015)
- Investors Count 3
Latest 10 of 11 funding rounds of Biofluidica with amounts and investors; the two latest post-money valuations are shown, the rest are part of the premium plan.
| Date | Amount | Transaction Name | Valuation | Lead Investors | Investors |
|---|---|---|---|---|---|
| Mar 2022 | Grant | – | – | ||
| Dec 2021 | $6M | Series B | – | – | – |
| Aug 2021 | $250,000 | Grant | – | – | |
| Mar 2021 | $5.98M | Series B | – | – | – |
| Nov 2019 | $3M | Debt – Conventional | – | – | – |
| Sep 2019 | $1.74M | Grant | – | – | |
| May 2019 | $291,545 | Grant | – | – | |
| Jul 2018 | $239,138 | Grant | – | – | |
| Jul 2017 | $4.14M | Series A | – | – | – |
| May 2016 | $2M | Seed | – | – | – |
3 investors in total: 3 institutional.
Investors in Biofluidica
Biofluidica has secured backing from 3 investors, including institutional investors. Prominent investors backing the company include NIH, HHS and Mizzou.
| Investor | Description | Founded Year | Domain | Location |
|---|---|---|---|---|
Multiple courses and degrees are offered across diversified academic streams. | 1839 | missouri.edu | United States | |
Drug discovery services are provided to the biopharma sector. | 1887 | nih.gov | United States | |
Public health and human services are overseen by HHS. | 1953 | hhs.gov |
Investor details for Biofluidica
The complete investor list, round-by-round participation and investor portfolios require an active premium plan.
- Complete investor list
- Round participation
- Investor portfolios
- Co-investor network
Verified entity values are shown only after access is granted.
People of Biofluidica
5 people are tracked at Biofluidica (4 in leadership, 1 in board & advisors).
| Name | Role | Group |
|---|---|---|
Steven A Soper | Co-Founder & CTO | Leadership |
Greg Studdard | Chief Executive Officer | Leadership |
Mateusz Hupert | Director, Instrumentation & Diagnostic Development | Leadership |
Doug Paulin | Chief Financial Officer | Leadership |
Philip Buchanan | Director | Board & advisors |
Complete people profiles for Biofluidica
Full employee and board profiles, team structure, tenure and professional contact details require an active premium plan.
- Full employee list
- Team structure
- Board tenure
- Professional contacts
Verified entity values are shown only after access is granted.
Timeline of Biofluidica
3 dated milestones of Biofluidica across 15 years, from founding to its latest funding, stage changes and deals.
- Founded Biofluidica is founded.
- Funding First funding round of $400K.
- Funding Latest funding round, Grant,.
Competitors of Biofluidica
Biofluidica has 3 listed competitors in our database, 3 of them funded. They include Guardant Health, GRAIL and Thrive Earlier Detection.
| Company Name | Domain | Founded | HQ Location | Total funding | Employees | Description |
|---|---|---|---|---|---|---|
| guardanthealth.com | 2012 | Redwood, United States | $557.5M | 1,351 | Digital sequencing technology for cancer detection is developed. | |
| grail.com | 2016 | Menlo Park, United States | $2B | 491 | Circulating tumor DNA is screened for early cancer detection. | |
| thrivedetect.com | 2019 | Cambridge, United States | $367M | 138 | Blood-based liquid biopsy tests for multiple cancer detection are provided. |
Detailed competitors of Biofluidica
The full competitor set, operating metrics and side-by-side benchmarks require an active premium plan.
- Full competitor set
- Operating metrics
- Benchmarks
- Competitive positioning
Verified entity values are shown only after access is granted.
Top companies in Genomics & Gene Therapy Platforms
3 companies that operate in the same segment as Biofluidica (Genomics & Gene Therapy Platforms) in United States, ranked by their profile score on The Company Check.
| Company | Description | Founded | Location | Total funding | Revenue | Employees |
|---|---|---|---|---|---|---|
mRNA-based therapeutics for diseases including cancer and infections are developed. | 2010 | Cambridge, Massachusetts, United States | USD 2.78 B | USD 1.94 B | 5,800 | |
Digital sequencing technology for cancer detection is developed. | 2012 | Redwood City, California, United States | USD 557.5 M | USD 982.02 M | 4,867 | |
Circulating tumor DNA is screened for early cancer detection. | 2016 | Menlo Park, California, United States | USD 2 B | USD 147.17 M | 1,141 |
Unlock complete access to The Company Check
Get unrestricted viewing across everything we track — from companies and brands to investors, funding rounds, acquisitions, financials, and more.
- Unlimited viewing on all profiles Companies, investors, financials, funding, acquisitions & directors
- Full access to every database India & global coverage, advanced filters and rich profile details
- Always-on access from your team account Single premium plan for everything you see on the portal
Related news about Biofluidica
Complete news archive for Biofluidica
Full article history, source details, and older brand coverage require an active premium plan.
- Full article archive
- Source and publication date
- Older coverage
- Brand-specific news history
Verified entity values are shown only after access is granted.
Frequently Asked Questions about Biofluidica
Biofluidica was founded in 2007 and raised its 1st funding round 8 years after it was founded.
Biofluidica is headquartered in Chapel Hill, United States. It is registered at Chapel Hill, North Carolina, United States.
Greg Studdard is the CEO of Biofluidica, as recorded in our data.
Biofluidica is a funded company, having raised a total of $18.12M across 11 funding rounds to date. The company's 1st funding round was a Seed of $2M, raised on Sep 2015.
Biofluidica was founded in 2007 and is based in Chapel Hill, United States, within the biotechnology sector. Operations focus on liquid biopsy systems that employ antibody-coated capture beds to isolate circulating tumor cells from blood samples. Clinical validation has been achieved for pancreatic, colorectal, ovarian, and breast cancers, enabling analysis for diagnostic purposes.
Biofluidica's top competitors include Guardant Health, GRAIL and Thrive Earlier Detection.
Biofluidica offers LiquidScan, Exosome Isolation, Fetal Cell Isolation, and CTC Isolation.
Biofluidica operates through Biofluidica, Inc..